Table 4.

De novo hepatitis B occurred in recipients with different serological status receiving lamivudine monotherapy

HBV serology	References	DNH/Total (%)
Anti-HBs (−), anti-HBc (−)	[29, 31, 45, 46]	1/16 (6.3)*
Anti-HBs (+), anti-HBc (−)	[16, 26, 31, 45, 46]	0/29 (0)†
Anti-HBs (−), anti-HBc (+)	[16, 29, 45, 46]	1/17 (5.9)¶
Anti-HBs (+), anti-HBc (+)	[16, 26, 31, 45, 46]	0/12 (0)

HBV hepatitis B, anti-HBs antibody against hepatitis B surface antigen, anti-HBc antibody against hepatitis B core antigen, DNH de novo hepatitis B

* Single patient did not compliant with lamivudine prophylaxis [29]

^†One patient was seroconverted for anti-HBc but remained negative for HBV DNA and hepatitis B surface antigen [31]

^¶Single patient did not compliant with lamivudine prophylaxis [29]